Core Viewpoint - Frontline Bio (688221.SH) is currently experiencing a decline in stock price, closing at 14.20 yuan with a drop of 2.67%, indicating a state of underperformance since its IPO [1] Group 1: IPO and Stock Performance - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial public offering (IPO) price of 20.50 yuan per share [1] - The stock reached its highest price of 35.53 yuan on the first day of trading, marking the peak since its listing [1] - The total number of shares issued during the IPO was 89.96 million, accounting for 25.01% of the total shares post-issuance [1] Group 2: Fundraising and Use of Proceeds - The total amount raised from the IPO was 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [1] - The company planned to use the raised funds for various projects, including the clinical development of an HIV fusion inhibitor, a combined therapy, a new transdermal analgesic patch, marketing network construction, and to supplement working capital [1] - The total fundraising from two rounds of issuance amounts to 2.044 billion yuan [4] Group 3: Underwriting and Strategic Investment - UBSAG, the underwriting institution, participated in the strategic placement of the IPO, acquiring 2,926,829 shares, which is 3.25% of the total issuance, for approximately 60 million yuan [2] - The lock-up period for the shares acquired by UBSAG is set for 24 months from the date of listing [2] Group 4: Subsequent Issuance - On September 22, 2022, Frontline Bio announced a specific issuance of 14,818,653 shares at a price of 13.51 yuan per share, raising a total of approximately 200.2 million yuan [3] - After deducting issuance costs, the net amount raised from this issuance was approximately 195.67 million yuan [3]

Group 1 - The stock of Frontier Biotech (688221.SH) closed at 14.89 yuan, with a decline of 4.18%, currently in a state of breaking issue [1] - Frontier Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total shares post-issuance, at a price of 20.50 yuan per share [1] - The highest stock price recorded on the listing day was 35.53 yuan, marking the peak since its listing [1] Group 2 - The total amount raised by Frontier Biotech during the issuance was 184.418 million yuan, with a net amount of 171.729 million yuan [1] - The company planned to use the raised funds for various projects, including the clinical research of an HIV fusion inhibitor, a combined therapy, a new transdermal analgesic patch, marketing network construction, and to supplement working capital [1] - The total issuance costs (excluding VAT) for the initial public offering were 12.689 million yuan, with underwriting and sponsorship fees amounting to 11.613 million yuan [1] Group 3 - UBSAG, the sponsoring institution, participated in the strategic placement of the issuance, acquiring 2,926,829 shares, which is 3.25% of the total issuance, for an amount of approximately 60 million yuan [2] - The lock-up period for the shares acquired by UBSAG is 24 months, starting from the date of listing on the Shanghai Stock Exchange [2] Group 4 - The actual controller of Frontier Biotech is Dongxie (Xie Dong), who holds American nationality and has permanent residency in China [3] - In a simplified procedure for issuing shares to specific objects, Frontier Biotech issued 14,818,653 shares at a price of 13.51 yuan per share on September 22, 2022, raising a total of approximately 200.2 million yuan [3] - After deducting issuance costs, the net amount raised from this issuance was approximately 195.67 million yuan [3] Group 5 - The total fundraising from the two issuances by Frontier Biotech amounts to approximately 2.044 billion yuan [4]

Group 1 - The core viewpoint of the news is that 前沿生物 (Frontier Biotech) is currently facing a decline in stock price, with its shares trading at 14.90 yuan, down 1.97%, and the company is in a state of stock price drop since its IPO [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial offering price of 20.50 yuan per share and a total issuance of 89.96 million shares, accounting for 25.01% of the total shares post-issuance [1] - The highest stock price recorded on the listing day was 35.53 yuan, marking the peak since its IPO [1] Group 2 - The total amount raised from the initial public offering (IPO) was 184.418 million yuan, with a net amount of 171.729 million yuan after deducting issuance costs [1] - The company planned to use the raised funds for various projects, including the clinical development of an HIV fusion inhibitor, a combined therapy, a new transdermal analgesic patch, marketing network construction, and to supplement working capital [1] - The total issuance costs for the IPO (excluding VAT) amounted to 12.689 million yuan, with underwriting and sponsorship fees being 11.613 million yuan [1] Group 3 - The actual controller of the company is DONGXIE (谢东), who holds American nationality and has permanent residency in China [3] - In a subsequent issuance on September 22, 2022, the company issued 14.819 million shares at a price of 13.51 yuan per share, raising a total of 200.200 million yuan, with a net amount of 195.667 million yuan after deducting issuance costs [3] - The total fundraising from both issuances amounts to 2.044 billion yuan [4]

Company Overview - Frontline Bio (688221.SH) closed at 15.82 yuan, experiencing a decline of 16.34%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total shares post-issuance, at a price of 20.50 yuan per share [1] - The highest stock price recorded since listing was 35.53 yuan on the first day of trading [1] Fundraising and Financials - The total amount raised from the issuance was 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [1] - The company aimed to raise 200.085 million yuan for various projects, including clinical research for HIV fusion inhibitors and pain relief patches, as well as for marketing network construction and working capital [1] - The total issuance costs (excluding VAT) for the initial public offering were 12.689 million yuan, with underwriting and sponsorship fees amounting to 11.613 million yuan [1] Strategic Participation - UBSAG, the sponsoring institution, participated in the strategic placement of the issuance, acquiring 2,926,829 shares, which is 3.25% of the total issuance, for an amount of approximately 60 million yuan [2] - The lock-up period for the shares acquired by UBSAG is set for 24 months from the date of listing [2] Additional Issuance - On September 22, 2022, Frontline Bio announced a specific issuance of 14,818,653 shares at a price of 13.51 yuan per share, raising a total of approximately 200.200 million yuan [3] - After deducting issuance costs of approximately 4.533 million yuan, the net amount raised was about 195.667 million yuan [3] - The total fundraising from the two issuances amounts to approximately 2.044 billion yuan [4]

Core Viewpoint - Frontier Biotech (688221.SH) reported a revenue of 58.64 million yuan for the first half of 2025, marking a year-on-year increase of 14.85%, but recorded a net loss attributable to shareholders of 97.35 million yuan, an improvement from a loss of 160 million yuan in the same period last year [1] Financial Performance - The company achieved a net cash flow from operating activities of -98.23 million yuan, compared to -89.19 million yuan in the previous year [1] - From 2018 to 2024, the net profit attributable to shareholders was -247 million yuan, -192 million yuan, -231 million yuan, -260 million yuan, -357 million yuan, -329 million yuan, and -201 million yuan respectively [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the same period was -167 million yuan, -202 million yuan, -240 million yuan, -311 million yuan, -399 million yuan, -355 million yuan, and -327 million yuan respectively [1] Initial Public Offering (IPO) Details - Frontier Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares at a price of 20.50 yuan per share [1] - The total amount raised from the IPO was 184.42 million yuan, with a net amount of 171.73 million yuan after expenses [2] - The company planned to use the raised funds for various projects, including the clinical development of HIV fusion inhibitors and pain relief patches, as well as for marketing network construction and working capital [2] Subsequent Fundraising - On September 22, 2022, the company issued 14.82 million shares at a price of 13.51 yuan per share, raising a total of approximately 200.20 million yuan, with a net amount of about 195.67 million yuan after deducting issuance costs [3] - The total fundraising from both IPOs amounted to approximately 2.04 billion yuan [4] Ownership Structure - The actual controller of Frontier Biotech is Dong Xie, who holds American nationality and has permanent residency in China [5]

Core Viewpoint - Frontline Bio (688221.SH) is currently trading at 19.63 yuan, reflecting a decline of 1.90% and is in a state of post-IPO price drop [1] Group 1: IPO Details - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total share capital post-issuance, at a price of 20.50 yuan per share [1] - The total funds raised from the IPO amounted to 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [2] - The company planned to use the raised funds for various projects, including the development of an HIV fusion inhibitor, clinical research for a combined therapy, and marketing network construction [2] Group 2: Financials and Shareholder Information - The actual controller of Frontline Bio is Dong Xie, who holds U.S. nationality and has permanent residency in China [3] - In a subsequent issuance on September 22, 2022, Frontline Bio issued 14.818 million shares at a price of 13.51 yuan per share, raising a total of approximately 200.2 million yuan, with a net amount of about 195.67 million yuan after deducting issuance costs [3] - The total amount raised from both fundraising rounds is approximately 2.044 billion yuan [4]

Group 1 - The core point of the news is that 前沿生物 (Frontier Biotech) is currently experiencing a decline in stock price, with a closing price of 20.07 yuan and a drop of 7.55% [1] - Frontier Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial public offering (IPO) of 89.96 million shares, accounting for 25.01% of the total shares post-issue, at a price of 20.50 yuan per share [1] - The highest stock price recorded since the IPO was 35.53 yuan, indicating that the stock is currently in a state of decline [1] Group 2 - The total amount raised from the IPO was 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [1] - The company planned to use the raised funds for various projects, including the clinical development of an HIV fusion inhibitor, a combined therapy, a new transdermal analgesic patch, marketing network construction, and to supplement working capital [1] - The total issuance costs for the IPO (excluding VAT) were 12.689 million yuan, with underwriting and sponsorship fees amounting to 11.613 million yuan [1] Group 3 - On September 22, 2022, Frontier Biotech announced a specific issuance of 14,818,653 shares at a price of 13.51 yuan per share, raising a total of approximately 200.200 million yuan [2] - After deducting issuance costs of approximately 4.533 million yuan, the net amount raised was about 195.667 million yuan [2] - The total fundraising from both the IPO and the subsequent issuance amounts to approximately 2.044 billion yuan [3]

Core Viewpoint - Frontline Bio has reported a net loss for seven consecutive years since its IPO in 2020, with a peak fundraising of 1.8 billion yuan through UBS Securities [1][4]. Financial Performance - In 2024, the company achieved total revenue of 129.47 million yuan, representing a year-on-year increase of 13.32% compared to 114.25 million yuan in the previous year [1][3]. - The net profit attributable to the parent company was -202.02 million yuan, and the net profit after deducting non-recurring gains and losses was -336.19 million yuan [1][3]. - For 2023, the company reported total revenue of 114 million yuan, a year-on-year increase of 34.82%, with a net profit of -329 million yuan, slightly improved from -357 million yuan in the previous year [3][4]. Historical Financial Data - From 2018 to 2022, the company's revenue figures were 1.91 million yuan, 20.86 million yuan, 46.62 million yuan, 40.50 million yuan, and 84.74 million yuan, respectively [4]. - The net profits for the same period were -247 million yuan, -192 million yuan, -231 million yuan, -260 million yuan, and -357 million yuan, indicating a consistent trend of losses [4]. IPO and Fundraising - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial share price of 20.50 yuan, raising a total of 1.84 billion yuan [4][5]. - The funds raised were intended for various projects, including clinical research for HIV treatments and pain relief patches, as well as for marketing network development and working capital [5].